Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03804983 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin
A NA study of Type 1 Diabetes Mellitus, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03804983: Completed NA study of Type 1 Diabetes Mellitus, sponsored by University of Virginia.
NCT03804983 is a NA study of Type 1 Diabetes Mellitus that has completed, run by University of Virginia. The registered enrollment target is 22 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03804983, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this proposed study is to assess the use of a new feature of the Control-IQ system, MyTDI.
Primary Outcome
The primary outcome for this study is the percent of time spent between 70mg/dL and 180mg/dL as computed by the number of CGM values falling in this interval divided by the total number of available CGM values. CGM gaps inferior to 3 hours will be linearly interpolated.
Conditions Studied
Interventions
- DEVICE Hybrid Closed Loop (HCL)
- DEVICE Control-IQ with MyTDI
Study Locations (1)
Virginia
- University of Virginia Center for Diabetes Technology - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-02-16 |
| Phase | NA |
What the finished NCT03804983 record still lists
NCT03804983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Hybrid Closed Loop (HCL) is the first listed.
NCT03804983 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03804983 about?
NCT03804983 is a clinical study titled "Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin". The purpose of this proposed study is to assess the use of a new feature of the Control-IQ system, MyTDI.
What is the current status of trial NCT03804983?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2019-01-15. Estimated completion is 2019-02-16.
What conditions does trial NCT03804983 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT03804983?
The interventions under investigation include: Hybrid Closed Loop (HCL) (DEVICE), Control-IQ with MyTDI (DEVICE).
Who is sponsoring clinical trial NCT03804983?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03804983 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03804983's enrollment target sits among peer trials
22 85th of 112 higher than 28 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI